Information Regarding Revolade

East Midlands Ambulance Service NHS Trust did not have the information requested.

Dear East Midlands Ambulance Service NHS Trust,

I would like to request information for the below questions.

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the following treatments:

• Revolade (eltrombopag)
• Nplate (romiplostim)
• Doptelet (avatrombopag)
• Tavlesse (fostamatinib)

Q2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?

Q3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:

rituximab
mycophenolate mofetil
surgery (splenectomy)

Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

Thank you for taking the time to answer these questions and I look forward to your response.

Yours faithfully,

Oliver Caswell

FOI, East Midlands Ambulance Service NHS Trust

Dear Oliver,
Thank you for your information request which we will process under the terms of the Freedom of Information Act 2000 and provide a response within the 20 working day statutory time limit.
If you have any queries about this process or wish to modify or amend your request, please contact me.

Regards

show quoted sections

FOI, East Midlands Ambulance Service NHS Trust

1 Attachment

Dear Oliver,
Please find attached our response to your recent information request.

Best wishes

show quoted sections